company

Radius Health

Radius Health is a biopharmaceutical company that developed abaloparatide, the bone-building drug the FDA approved as Tymlos in 2017 to reduce fractures in postmenopausal women with osteoporosis.

radiuspharm.com

President and CEO

Robert Ward

Key facts

Company: Science-driven biopharmaceutical company based in Waltham, Massachusetts (Nasdaq: RDUS), focused on osteoporosis, oncology and endocrine diseasessource
Drug: Developed abaloparatide, approved by the FDA as Tymlos on April 28, 2017source
First in class: Tymlos was the first new anabolic bone-building agent for postmenopausal women with osteoporosis in the United States in nearly 15 yearssource

WYDE coverage of Radius Health

WYDE Newsroom has published one article about Radius Health, on Oct 3, 2026. Radius Health is the subject of 1 story. The most recent is Abaloparatide Cut New Spinal Fractures by 86% in a Trial of 2,463 Women With Osteoporosis.

Healthcare

Abaloparatide Cut New Spinal Fractures by 86% in a Trial of 2,463 Women With Osteoporosis

The bone-building drug abaloparatide, sold as Tymlos, cut new spinal fractures by 86 percent and nonvertebral fractures by 43 percent over 18 months in the 2,463-woman ACTIVE trial published in JAMA.

Oct 3, 2026 · 3 min read · Subject of the story

Reported alongside Radius Health

U.S. Food and Drug Administration · in 1 story with Radius Health

Sources

Bone Health & Osteoporosis Foundation: FDA Approves Radius Health's TYMLOS (abaloparatide)

Track the institutions that move money.

Data-driven coverage, every week.